Please check your internet connection and try again.
# Dexamethasone in Chronic ITP
## Overview
Dexamethasone is a high-potency synthetic glucocorticoid used for the treatment of Immune Thrombocytopenia (ITP). In the context of chronic ITP (or initial management of newly diagnosed ITP), it is utilized for its rapid onset of action in modulating the immune system and inhibiting phagocytosis of antibody-coated platelets.
## Primary Indications
* First-line therapy for newly diagnosed ITP.
* Rescue/salvage therapy for chronic or refractory ITP.
## Adult Dosing
* **Standard Regimen:** 40 mg orally once daily for 4 consecutive days.
* **Cycles:** This 4-day course may be repeated every 14 to 28 days depending on hematologic response and patient tolerance.
* **Maximum:** Do not exceed 40 mg/day.
## Pediatric Dosing
* **Standard Regimen:** 0.6 mg/kg/day (maximum 40 mg/day) orally once daily for 4 consecutive days.
* **Cycles:** May be repeated every 2 to 4 weeks based on institutional protocols and clinical response.
## Dose Adjustments
* **Hepatic Impairment:** No specific adjustment, but use with caution due to slowed metabolism.
* **Renal Impairment:** No dose adjustment necessary.
* **Tapering:** While high-dose "pulse" dexamethasone is often stopped abruptly due to the short duration (4 days), patients on long-term corticosteroid therapy require a gradual taper to prevent adrenal insufficiency.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or any component of the formulation.
* Administration of live or live-attenuated vaccines during immunosuppressive doses.
## Adverse Effects
* **Common:** Insomnia, mood lability (anxiety, aggression, depression, euphoria), fluid retention, hyperglycemia, and dyspepsia.
* **Serious:** Avascular necrosis, peptic ulcer disease, increased susceptibility to infection, exacerbation of masked latent chronic infections (e.g., TB, Hepatitis B), and hypertension.
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., phenytoin, carbamazepine, rifampin) may decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors:** (e.g., ketoconazole, ritonavir) may increase dexamethasone levels and toxicity.
* **NSAIDs/Anticoagulants:** Increased risk of gastrointestinal bleeding.
* **Antidiabetic agents:** Dexamethasone may antagonize glycemic control.
## Monitoring
* **Baseline:** Complete blood count (CBC) with differential, fasting blood glucose, blood pressure, and screening for latent TB/Hepatitis if clinically indicated.
* **Ongoing:** Monitor platelet counts (weekly/bi-weekly during pulse phases), glucose levels, blood pressure, and signs of secondary infection or psychiatric changes.
## Clinical Pearls
* **Efficacy:** High-dose pulse dexamethasone is generally preferred over prednisone for initial treatment because it provides a more rapid rise in platelets and fewer long-term side effects due to the limited duration of therapy.
* **GI Protection:** Consider the use of a proton pump inhibitor (PPI) or H2-receptor antagonist, especially in patients with a history of peptic ulcer disease.
* **Administration:** Administer with or immediately after food to mitigate gastric irritation.
* **Variation:** Always refer to local facility hematology/oncology protocols, as repeat cycle intervals and salvage definitions vary by clinical practice.
***
**Educational Disclaimer:** This information is intended for educational purposes for healthcare professionals. Clinical practice guidelines, institutional protocols, and patient-specific factors vary. Always verify current prescribing information, package inserts, and hospital guidelines before administering medication.
